Rx Sight, Inc. RXST
We take great care to ensure that the data presented and summarized in this overview for RxSight, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RXST
View all-
Ra Capital Management, L.P. Boston, MA3.74MShares$46.5 Million1.96% of portfolio
-
Black Rock Inc. New York, NY2.4MShares$29.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.39MShares$29.7 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC2.18MShares$27.1 Million0.0% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI1.77MShares$22 Million0.08% of portfolio
-
Brown Capital Management LLC Baltimore, MD947KShares$11.8 Million0.74% of portfolio
-
State Street Corp Boston, MA899KShares$11.2 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny898KShares$11.2 Million0.01% of portfolio
-
Divisadero Street Capital Management, LP Miami, FL885KShares$11 Million2.79% of portfolio
-
Geode Capital Management, LLC Boston, MA863KShares$10.7 Million0.0% of portfolio
Latest Institutional Activity in RXST
Top Purchases
Top Sells
About RXST
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
Insider Transactions at RXST
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 03
2025
|
Robert J Palmisano |
BUY
Grant, award, or other acquisition
|
Direct |
10,752
+20.76%
|
-
|
|
Jun 03
2025
|
Shweta Maniar |
BUY
Grant, award, or other acquisition
|
Direct |
10,752
+37.22%
|
-
|
|
Jun 03
2025
|
Robert Keith Warner |
BUY
Grant, award, or other acquisition
|
Direct |
10,752
+20.76%
|
-
|
|
Jun 03
2025
|
Tamara Fountain |
BUY
Grant, award, or other acquisition
|
Direct |
10,752
+23.22%
|
-
|
|
Jun 03
2025
|
William J Phd Link |
BUY
Grant, award, or other acquisition
|
Direct |
10,752
+22.12%
|
-
|
|
Jun 03
2025
|
Jesse Anderson Corley |
BUY
Grant, award, or other acquisition
|
Direct |
10,752
+17.94%
|
-
|
|
Jun 03
2025
|
Bakker Juliet Tammenoms |
BUY
Grant, award, or other acquisition
|
Direct |
10,752
+18.26%
|
-
|
|
Jun 03
2025
|
Julie Andrews |
BUY
Grant, award, or other acquisition
|
Direct |
10,752
+20.76%
|
-
|
|
Jun 02
2025
|
Eric Weinberg |
BUY
Exercise of conversion of derivative security
|
Direct |
188,002
+49.04%
|
$564,006
$3.93 P/Share
|
|
Apr 14
2025
|
Shelley B Thunen |
BUY
Exercise of conversion of derivative security
|
Direct |
7,792
+16.89%
|
$31,168
$4.34 P/Share
|
|
Mar 12
2025
|
Tamara Fountain |
SELL
Open market or private sale
|
Direct |
7,000
-22.02%
|
$175,000
$25.71 P/Share
|
|
Jan 22
2025
|
Shweta Maniar |
SELL
Open market or private sale
|
Direct |
3,519
-32.28%
|
$105,570
$30.87 P/Share
|
|
Jan 16
2025
|
Jesse Anderson Corley |
BUY
Open market or private purchase
|
Indirect |
1,767
+35.5%
|
$54,777
$31.13 P/Share
|
|
Jan 15
2025
|
Jesse Anderson Corley |
BUY
Open market or private purchase
|
Indirect |
1,443
+50.0%
|
$44,733
$31.18 P/Share
|
|
Nov 29
2024
|
Ilya Goldshleger |
SELL
Open market or private sale
|
Direct |
3,105
-6.85%
|
$142,830
$46.08 P/Share
|
|
Nov 29
2024
|
Ilya Goldshleger |
BUY
Exercise of conversion of derivative security
|
Direct |
3,105
+6.41%
|
$46,575
$15.08 P/Share
|
|
Nov 26
2024
|
Ilya Goldshleger |
SELL
Open market or private sale
|
Direct |
3,100
-6.84%
|
$139,500
$45.88 P/Share
|
|
Nov 26
2024
|
Ilya Goldshleger |
BUY
Exercise of conversion of derivative security
|
Direct |
3,100
+6.4%
|
$46,500
$15.08 P/Share
|
|
Nov 26
2024
|
Shweta Maniar |
SELL
Open market or private sale
|
Direct |
3,782
-25.76%
|
$170,190
$45.88 P/Share
|
|
Nov 22
2024
|
Ilya Goldshleger |
SELL
Open market or private sale
|
Direct |
3,100
-6.84%
|
$139,500
$45.0 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 86K shares |
|---|---|
| Exercise of conversion of derivative security | 312K shares |
| Open market or private purchase | 25.7K shares |
| Open market or private sale | 113K shares |
|---|